Topline Results from Paltusotine Phase 3 PATHFNDR-2 Study

March 19, 2024

Crinetics will hold a live webcast on Tuesday, March 19 at 8:30 a.m. ET to discuss topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.